ALK and lung carcinoma: Personalized medicine approaches and personalized biomarker identification have successfully been applied in other disease models including anaplastic lymphoma kinase biomarker for lung cancer (Cutter and Liu, 2012) or pharmacogenomic approaches in multiple sclerosis (Zhou et al., 2019).